Base Edited “Universal” Donor CAR T-Cell Strategies for Acute Myeloid Leukaemia

Investigators reported that monotherapy using base-edited “universal” donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of acute myeloid leukaemia in immunodeficient mice when antigen expression was homogenous. Still, the combined use of BE-CAR33 and BE-CARCLL-1 T cells was required to address heterogeneous CLL-1^-/+CD33^-/+ disease.